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ABSTRACT
Various studies show a variety of interventions for radiotherapy-induced skin toxicity.
Radiotherapy-induced skin toxicity is the most common side effect for women with breast cancer
who undergo radiotherapy sessions. Intervention agents include topical creams, barrier films, oral
agents, as well as laser therapy. However, despite the variety of intervention agents available, there
is still a lack of accepted guidelines to manage radiotherapy-induced skin toxicity. This thesis aims
to conduct a systematic review and meta-analysis of published randomized controlled trials with
the primary purpose of exploring the available intervention methods to prevent radiotherapyinduced skin toxicity and evaluate the effects of different interventions for radiotherapy-induced
skin toxicity among breast cancer patients. A total of 37 studies were included in the study. The
overall results for the study revealed that the available interventions for radiotherapy-induced skin
toxicity reside within non-steroid creams, steroid creams, oral supplements, laser therapy, and
films. In addition, oral supplements were most effective in preventing radiotherapy-induced skin
toxicity. Other groups showed preventive results but were not statistically significant, but other
factors were taken into consideration. This systematic review and meta-analysis provide insight to
oncologists by helping make better clinical decisions for their patients, having comprehensive
evidence readily available to offer the best treatment for radiotherapy-induced skin toxicity and to
have a more efficient overall treatment for breast cancer patients. Finally, this systematic review
and meta-analysis can guide a path that leads to an accepted treatment for radiotherapy-induced
skin toxicity.
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Chapter I. INTRODUCTION
Radiotherapy is one of the most common treatments for breast cancer. Radiotherapy can
target partial, whole breast (after lumpectomy), or chest wall (after mastectomy) with or without
coverage of surrounding areas [1]. However, this method of treatment has given rise to various
radiotherapy-induced toxicities that affect the original treatment regimen as well as the quality of
life for patients with breast cancer [1].
One of the most common radiotherapy-induced toxicities is related to the broad spectrum
of radiation dermatitis [2]. This term encompasses different skin toxicities that include mild to
more severe conditions. According to Sloan and Alcorn [1], acute skin reactions occur up to 95%
in patients undergoing radiotherapy. Signs of radiotherapy-induced acute skin toxicities occur
within 30 days of the completion of regimen. Nevertheless, there is an increased peak of acute skin
toxicity from 1-2 weeks after finishing the treatment [1]. The onset of acute skin toxicities is
diagnosed clinically through a formal assessment system that evaluates the degree of the patient’s
skin toxicity. The National Institute of Health (NIH) published the Common Terminology Criteria
for Adverse Events (CTCAE), and it is the most widely used assessment system for scoring the
degree of acute skin toxicity [3]. The CTCAE takes into account that acute skin toxicity is coined
around the amount of desquamation and erythema that develops acutely as a result of radiation
therapy [1]. These two conditions are graded together on a scale from 0-5, where 0 shows no
symptoms, and 5 is the most severe status.
Radiotherapy-induced skin toxicities have been presented in many studies as factors that
affect the quality of life for many individuals with breast cancer and other cancers [4]. According
to Amber et al. radiation-induced skin toxicities can cause distress and a decreased quality of life
[5]. Such assessment systems include the Functional Assessment of Cancer Therapy-Breast
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(FACT-B) and European Organization for Research and Treatment of Cancer-Breast (EORTCB23) [1]. The decreased quality of life leads patients to look for interventions to alleviate pain,
local discomfort, fibrosis, and local inflammation [1].
Also, radiotherapy-induced skin toxicities interrupt the original radiation regimen and
affect the overall treatment for breast cancer. According to Kang and colleagues, 90% of patients
that receive high radiation dose develop skin toxicity, which leads to limitations of dose delivery
and affects overall treatment outcome [6]. Various types of interventions have been studied to test
their effect on radiotherapy-induced skin toxicity. For example, antioxidants are free radical
scavengers that alter the release of cytokines affecting cutaneous and systemic changes [5].
Epidermal growth factor (EGF)-based cream treatments are topical agents that contain wound
healing properties [6]. Natural products, like honey and aloe vera that contain safe healing
properties for wounds, are being studied as alternatives to pharmaceutical treatments [7]. However,
even though these different interventions have been studied, they have not been accepted as a
standard method of care.
Radiotherapy-induced skin toxicity has become an inevitable side effect in breast cancer
patients [8]. However, there is a lack of conclusive data that supports or refutes many different
types of interventions. In addition, because of this lack of data, new products are being introduced
that do not provide evidence of benefits nor effectiveness [8], which creates a surplus of possible
intervention agents and still a lack of an accepted preventive measure. The purpose of this
systematic review is to explore the available intervention methods and explore their effects in
preventing radiotherapy-induced skin toxicity among breast cancer patients.
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Chapter II. REVIEW OF THE LITERATURE
1. Breast Cancer
Throughout the world, breast cancer is one of the most commonly diagnosed cancer and
the leading cause of cancer death in women [9]. Similarly, in the United States, breast cancer is
the most frequently diagnosed cancer and the second leading cause of death in women [10].
Specifically, breast cancer accounts for over 260,000 new cases and causes over 40,000 deaths a
year in American women [11]. Over the most recent five year period (2012-2016), the breast
cancer incidence rate increased slightly by 0.3% per year [10]. Also, in the same time periods,
death rates have declined 2.1% in Hispanics, 1.5% in blacks, and 1.0% in whites [10]. Declines in
breast cancer mortality could be due to the improved access to high-quality prevention, early
detection, and treatment services to women [10].
Throughout the years, breast cancer has been heavily studied through research and clinical
trials. Breast cancer is characterized as a disease in which cells grow uncontrollably in the breast
tissue or may grow in the form of a tumor [9]. The diagnosis of breast cancer is related to the
presence of malignant epithelial cells. Breast cancers are heterogeneous in origin because
malignancies can develop from different epithelial tissues within the breast [12]. There are
different types of breast cancer: for example, ductal carcinoma in situ (DCIS), micro invasive
breast cancer, and breast sarcoma. However, once the cancer has spread to other parts of the body,
it is considered a metastatic breast cancer [9].
Signs and symptoms vary by individuals, but the most common signs include a breast mass
[9]. A breast mass is a classic characteristic of a cancerous lesion and are usually hard and
3

immovable, with irregular borders. Severe signs and symptoms are involved with axillary
adenopathy or skin manifestations such as erythema or dimpling of the overlying skin [6]. In
addition, breast ultrasound, magnetic resonance imaging (MRI), and pathology can help
distinguish between benign and malignant growths within the breast tissue. By using these
techniques, a diagnosis can be developed. When a diagnosis is established, it is important to clearly
define the extent or severity of the disease in order to manifest the most appropriate treatment
option.
Researchers and doctors look for the best possible ways to treat and extend the lives of
many patients. Breast cancer is typically characterized as an early-stage or locally advanced.
Depending on the stage of cancer, different treatment methods, such as surgery, radiotherapy, and
chemotherapy, are available to treat breast cancer in the best possible way [13]. For early-stage
breast cancer, the primary treatment is breast-conserving therapy (BCT), which includes breast
conserving surgery (as known as lumpectomy) and adjuvant radiotherapy and hormone therapy.
The main purpose of BCT is to treat the cancer and remove an affected area in the breast while
providing longer survival, a cosmetically acceptable breast, and a low rate of recurrence of breast
cancer [14]. Other treatment options include a mastectomy which completely removes the affected
breast. For locally advanced breast cancer, treatment options may be more aggressive.
Neoadjuvant systemic therapy is used to treat locally advanced breast cancer with the goals of
inducing a tumor shrinkage before surgery and enabling breast conservation [15]. Neoadjuvant
systemic therapy treatment options result in good prognosis in patients with breast cancer [15].
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2. Radiotherapy
Radiotherapy is one of the most common treatments for breast cancer. It uses high doses
of radiation in order to destroy cancer cells and shrink the size of tumors [16]. Through various
rounds of radiotherapy and weeks of treatment, the cancer cells’ DNA is damaged [16]. Once the
DNA is damaged, the cancer cell will stop growing and dividing, and eventually, the body will
remove it. Even after radiotherapy is over, cells will continue to die as a result of radiation, which
is still present in the body [17]. It is especially used to treat those patients who are at high risk for
local recurrence [17]. Often time, radiotherapy is used after a lumpectomy or mastectomy and used
simultaneously with other treatment like chemotherapy or hormone therapy [18].
There are two main categories of radiotherapy treatments: internal and external beam [17].
Internal radiotherapy works by having a solid or liquid source of radiation placed inside of the
body. Internal radiotherapy with a solid source is called brachytherapy. Different types of media,
such as ribbons, seeds, or capsules, are placed right by the tumor, and they will give off radiation
[17]. On the other hand, liquid source internal beam radiotherapy is called systemic treatment
because the treatment travels throughout the body via blood and tissues and seeks to kill cancer
cells which is given as an oral medication or intravenously [17].
With external beam radiotherapy, the patient is receiving high-energy x-rays externally
through a machine that points directly at a specific part of the body [19]. The machine may move
around depending on which area of the body the cancer is located in. In addition, external beam
radiotherapy is considered a local treatment because of the specificity of the body target area [19].
External beam radiotherapy is the most common version of treatment and has different variants in
which the treatment is introduced [19]. For example, three-dimensional conformal radiation
therapy (3D-CRT) delivers radiation beams from different directions intended to match the shape
of the tumor precisely [19]. Intensity-modulated radiation therapy (IMRT) is similar to 3D-CRT,
5

but it changes the strength of certain beams in specific areas [19]. Proton beam radiation therapy
uses proton beams instead of photons or electrons thus, causing little damage to the tissues they
pass through but are precise at killing cells through their path [19]. Usually, external beam
radiotherapy makes patients receive treatment daily five times a week for several weeks, which is
referred to as conventional fractionation. However, some doctors prefer patients receive a slightly
higher dose per day for less period of time, which is known as hypofractionation [19].
Radiotherapy regimen all depends on the size, location, and type of cancer.
Radiotherapy plays an important role in treating breast cancer and can take on many forms
to target different types of cancers as well as different types of patients. With time, treatments have
improved with effectiveness in targeting tumor cells. However, many patients do suffer from the
negative side effects of treatment by killing healthy cells that are proximal to cancer cells [17].
3. Radiotherapy Side Effects
Side effects can play a crucial role in cancer radiotherapy. In some instances, side effects
can affect the ability to do leisure things or go to work [20]. It all depends on what the patient is
feeling. Side effects can vary from person to person, and for different variations of treatment [21].
Also, any side effects depend on the different types of cancer, the location of cancer, the dose of
radiation, and overall health [20].
Radiotherapy side effects can be characterized by early and late effects. Early side effects
occur during or right after radiotherapy treatment. Usually, these side effects are mild, treatable,
and usually gone within a few weeks after treatment ends [20]. Also, early side effects are related
to the area that is being treated [20]. On the other hand, late side effects can take months or years
to develop, and usually are a result of healthy tissue receiving radiation [20]. Late side effects
depend on the treated area as well as the dose that was used [20].
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Every person reacts differently to treatment [20]. One of the most common side effects of
radiotherapy is fatigue. Patients may feel physically, mentally, and emotionally tired [20]. Fatigue
usually gets worse as treatment goes on as well with the stress that sick patients may feel. It is
important for patients to manage fatigue because it will improve their care.
Skin problems are another major side effect that many patients deal with while receiving
radiotherapy [20]. After the radiotherapy session, the skin may look red, irritated, swollen,
blistered, sunburned, or even tanned [20]. Often times, these problems go away once treatment
ends, and sometimes the treated skin may remain darker or more sensitive than it was before [20].
These skin complications are called “radiation dermatitis” or skin toxicity. Other common side
effects include hair loss and low blood count.
4 . Radiotherapy-induced Skin Toxicity
Skin toxicity is one of the main adverse effects as a result of radiotherapy, and skin changes
can be experienced by up to 95% of patients who underwent treatment [4]. Skin toxicity can be
classified into acute or chronic and can have a range of symptoms and visual signs. The most
common symptoms include pain and discomfort, and the most common signs can include dry
desquamation, general erythema, ulceration, telangiectasias, and fibrosis [4].
Many factors that increase the risk of skin toxicity have been identified, and the severity of
the reactions is related to both internal and external factors [4]. Internal factors such as genetic
influences related to mutations in DNA repairing mechanisms have been studied closely [4]. For
example, telangiectasia is closely related to the Ataxia-Telangiectasia Mutated (ATM) gene, and
patients with the disease are more likely to develop serious complications after radiotherapy
because they cannot repair the damaged DNA [4]. External factors include surgery type, radiation
site (breast or chest wall), other cancer treatments, the total radiation dose, fractioned delivery
schedules, volume of irradiated tissue, and the internal sensitivity of the surrounding tissue [4].
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Different mechanisms associated with radiotherapy-induced skin toxicity include an
inflammatory response and oxidative stress. The inflammatory response to radiation is mainly
caused by pro-inflammatory cytokines, chemokines, receptor tyrosine kinase, and adhesions
molecules [4]. These factors can create a local inflammatory response of eosinophils and
neutrophils, leading to self-tissue damage and loss of protective barriers within the skin [4].
Oxidative stress is related to the redox system of cells. Radiotherapy causes radiolysis of water
within cells and tissues, leading to reactive oxidative species and reactive nitrogen species [4]. The
production of reactive oxidative species goes through molecular changes, which lead to DNA,
lipid, and protein damages of cells [4]. These internal damages eventually result in skin damage
as well. After radiotherapy-induced cell damage, the cells die in many forms due to inflammation
and oxidative stress, promoting each other [4].
Understanding the mechanism behind skin toxicity gives a better understanding of the signs
and symptoms that patients suffer. In addition, signs and symptoms are directly related to different
scoring systems that physicians use in order to assess skin toxicity. Skin toxicity is usually assessed
using the criteria established by the Radiation Therapy Oncology Group (RTOG) (Table 1) or the
National Institute of Health’s (NIH) Common Terminology Criteria for Adverse Events (CTCAE)
(Table 2) [22]. Both systems use a 6-point scale ranging from 0 (No change) to 5 (death) [22].
5. Skincare management for skin toxicity
Skincare management for radiotherapy-induced skin toxicity varies between many
different institutions [23]. Traditional skincare management, including topical steroids, creams,
ointments, and hydrogel films, have been widely used in clinics [4]. Topical creams and ointments
have been studied closely because they are agents that have an immediate contact with the skin
injury. For example, EGF-based cream is known to participate in a protective and therapeutic
manner against mucositis or skin injury in animal models caused by radiotherapy [6]. The EGF8

based creams contains 0.005% recombinant human EGF with wound healing properties in addition
to ingredients such as ceramide, hyaluronic acid, Inca omega oil, Portulaca oleracea extract,
mango butter, and meadowfoam oil [6]. Furthermore, EGF-based creams stimulate the
proliferation of fibroblasts and keratinocytes during the healing process [6]. Further research is
taking place in order to have reliable evidence for EGF-based cream as accepted management for
skincare. Another topical agent that is under study is Calendula-based cream. Calendula-based
cream is derived from a plant of the marigold family called Calendula Officinalis [24]. This agent
is able to prevent oxidative stress, which makes Calendula-based cream, theoretically, an ideal
treatment to manage skin toxicity. However, more research is taking place on Calendula and its
properties because many studies have given mixed results [24] when compared to other agents.
Other agents include hydrogel films that aim to rehydrate and cool wound areas caused by
radiotherapy [25]. These films are considered non-steroid based products because they are made
of other ingredients and manifest different properties. For example, “Hydrofilm” is a transparent
and thin polyurethane film dressing that sticks to the skin surface by a hypoallergenic acrylic
adhesive and is known to be sterile, semi-permeable, and bacteria-proof [25]. In addition, the
Hydrofilm can remain on the skin for several weeks without causing trauma at the time of removal
[25]. Similarly, another type of film called “Mepitel,” made out of soft silicone technology, is used
in the same way as Hydrofilm. This film is an adhesive that molds to the skin and allows for
comfortable wear and does not cause trauma at the time of removal [26]. Both hydrogel films
promote a moist healing environment and present a different way to manage skin toxicity.
However, studies show that it is possible to improve their application technique [26], and further
research needs to take place in order to have reliable evidence.
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In addition to traditional skincare management, other prodcuts have been studied as
alternatives. Antioxidants have been studied because of their counteractive mechanisms against
inflammation and oxidative stress caused by radiotherapy. One of the most studied antioxidants is
superoxide dismutase because it is known to scavenge radiotherapy oxidative stress and has antiinflammatory properties [5]. Another example of antioxidants includes the polyphenol family,
which also contains agents that have a reverse effect on oxidative stress and have antiinflammatory properties [5]. Antioxidants have a positive effect on skincare management after
radiotherapy but have been controversial because studies have shown they interfere with tumor
apoptosis following radiotherapy on the existing cancer [5]. More research is taking place with
various antioxidants.
Finally, many studies have been conducted on natural products for skincare management
following radiotherapy as an alternative for traditional agents. For example, studies have shown
how medicinal honey gauze is effective and safe in treating many wounds by reducing pain and
irritation because of anti-inflammatory properties [7]. Similarly, chamomile extract has been
studied with the same purpose. Chamomile extract has anti-inflammatory properties in addition to
spasmolytic properties [27] and is known to alleviate mucositis. In addition, chamomile extract
has antibacterial properties as they are effective against gram-positive organisms and candida [27].
It is important to note that natural products have given positive results in skincare management
after radiotherapy but continue to be studied.
6. Importance of research
Radiotherapy-induced skin toxicity has become a prominent side effect affecting women
diagnosed with breast cancer. The grade of the skin toxicity can be severe and can interrupt the
original radiotherapy treatment for patients. In addition, the quality of life that the patients
undertake can be difficult to manage when pain, irritation, and discomfort are caused by skin
10

toxicity. Many skincare management agents following radiotherapy have been studied, but there
is a lack of conclusive evidence that these agents are beneficial or effective. Some studied skincare
management agents have mixed results, and others need further testing. The traditional skincare
management agents vary between clinics and institutions, some with good outcomes and others
with bad ones; however, there are no accepted guidelines to prevent radiotherapy-induced skin
toxicity [17]. Finding a beneficial and effective skincare management agent is critical in order to
prevent the development of skin toxicity in breast cancer patients undergoing radiotherapy, thus
promoting an uninterrupted radiotherapy regimen and an improved quality of life. This study aims
to explore the available skincare management agents and evaluate their effectiveness in preventing
radiotherapy-induced skin toxicity. This study is important and may guide future research in
finding a best-available skin care management for women with breast cancer undergoing
radiotherapy.
1).Research question: Which intervention methods are available, and which one is most effective
in preventing radiotherapy-induced skin toxicity among patients with breast cancer?
2).Objectives:
The current systematic review aims to:
Aim 1: Explore the available intervention methods to prevent radiotherapy-induced skin toxicity
among breast cancer patients.
Aim 2: Evaluate the effect of different interventions for radiotherapy-induced skin toxicity among
breast cancer patients.
3).Hypotheses:
Hypothesis 1: Many interventions for radiotherapy-induced skin toxicities among patients with
breast cancers will be identified, and they will include pharmaceutical agents (i.e., steroid cream,
skin barriers) and natural products (i.e., honey, aloe vera).
11

Hypothesis 2: Breast cancer patients that receive any type of preventive interventions for
radiotherapy-induced skin toxicity, which contain wound healing attributes, would have the same
level of skin toxicity (i.e., incidence rate of grade ≥ 2, or mean assessment score) at the end of
radiotherapy compared to patients who are assigned to a control group (i.e., placebos, standard of
care, or no treatment).
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Chapter III. METHODS
1.Study Design
A systematic review and meta-analysis followed the guidelines of Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA) to identify the available preventive
interventions for radiotherapy-induced skin toxicities among patients with breast cancer
systematically and to compare the effects of these interventions on the prevention of grade ≥ 2
acute skin toxicity through the published literature.
2.Inclusion and Exclusion Criteria
The inclusion and exclusion criteria were developed using the population, intervention,
comparison, outcome, and study (PICOS) criteria (Table 3). Only randomized controlled trials
published in the English language that test preventive interventions for radiotherapy-induced skin
toxicity in breast cancer patients were included in the study. “Preventive interventions” were
defined as methods that were 1) introduced to patients before or at the start of radiotherapy and 2)
either pharmaceutical agents or natural agents. Studies that reported skin toxicity as the primary
outcome using RTOG or CTCAE scales were included as well. Any review article, protocol,
retrospective study, nonrandomized study, and case report/series were excluded. Also, studies that
used mixed-gender or male-only participants, those that did not report radiotherapy-induced skin
toxicity grade or severity as an outcome variable, those that tested interventions for treating
radiation dermatitis, and those that included patients with cancers other than the breast were also
excluded.
3. Study Identification and Search Strategy
A comprehensive search strategy was used to amplify the selection of qualified studies,
which evaluated the preventive interventions for radiotherapy-induced skin toxicities among
patients with breast cancer in the clinical setting. Specific keywords included: “breast”,
13

“mammary”, “cancer”, “malignant”, “intervention”, “radiotherapy”, “radiation dermatitis”, and
“skin toxicity” and their synonyms. These key terms were searched through four databases: Web
of Science, Medline, PsycINFO, and CINAHL. The search results were limited to randomized
controlled trials or randomized clinical trials and English language articles. Identified studies were
exported to the Endnote library separately for each database, and full-text was searched and
attached before being imported to the systematic review software for screening.
4. Selection of Studies
Search results were screened by two reviewers according to the inclusion and exclusion
criteria. DistillerSR software (Evidence Partners, Inc.; Ottawa, Canada) was used to facilitate the
screening process of identified studies by title, abstract, and full-text reviews. Any disagreements
were discussed and resolved amongst the reviewers.
5. Data Extraction and Quality Assessment
Essential data relevant to PICOS criteria were extracted using the pre-defined forms in the
Excel program. First author’s last name, publication year, study location, study design
characteristics (number of study arms, number of patients, use of placebos/controls, use of
blinding), patient characteristics (age, race/ethnicity, cancer stage, surgery type, other treatments),
intervention/control characteristics (length of intervention, pharmaceutical or natural agents), and
skin toxicity reporting outcomes (reporting scales, the incidence of skin toxicity grade ≥ 2 or
average grade ± standard deviation, assessment timing) were extracted from each study that met
inclusion criteria after screening. Radiotherapy information included the length of treatment, total
dose, fractionation, boost, and radiation site (breast or chest wall). Finally, data extraction was
verified by another reviewer to increase the validity of the data.
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Chapter IV. RESULTS
A total of 83 studies for radiotherapy-induced skin toxicity were identified. Of those, 46
studies were excluded. 12 studies did not use RTOG or CTCAE assessment tool, 12 studies did
not have sufficient information, 7 studies were not randomized controlled trials, 6 studies were not
relevant to breast cancer, 2 studies did not have prevention purposes, 2 studies were duplicates, 2
studies were very similar to other included studies, 1 study had insufficient information, and 1
study had inconclusive results. In the end, a total of 37 studies met the inclusion criteria and were
included in the qualitative analysis and 34 studies were included in the quantitative analysis
(Figure 1)
All 37 included studies were randomized controlled trials that tested interventions for the
prevention of radiotherapy-induced skin toxicity. The included studies were from a variety of
regions and were published between the years 2000 and 2019. All participants of the studies had
histological proof of diagnosed breast cancer, were planned to or were receiving radiotherapy, and
had a radiotherapy duration of about 5 to 6 weeks with a dose of 50-52Gy. The site where patients
would receive radiotherapy would vary between whole breast, chest wall, supraclavicular, and
axillary/nodal region. Some patients would receive a boost of radiotherapy in the tumor bed of 916Gy. Participants in the studies were randomly assigned to control and intervention groups.
Control group agents would vary between placebo, standard of care, other treatment , and no
treatment groups (Table 4)
Interventions included non-steroid creams, steroid creams, laser therapy, oral supplements
and films. Of these, 27 non-steroid applications (includes herbal exctracts, petrolatum-based,
15

hyaluronic-based, trolamine-based, and other) , 9 steroid applications, 2 laser therapy, 3 oral
supplements (includes glutamine, bran, and curcumin), and 4 films were identified (Table 6). Two
studies by Omvidari 2007 and Shaw 2013 were 3 armed randomized control trial. The study by
Omvidari compared 2 steroid creams to a non-steroid cream, and Shaw study compared 2 steroid
creams to a film. Each intervention had its own specific instructions of application or usage. Some
interventions were used from the first day of radiotherapy and would last until last day of
radiotherapy or up until 6-week post radiotherapy.
Out of the 37 included studies, the intervention groups of 11 studies did not show
effectiveness in preventing grade ³ 2 skin toxicity. The study by Fife using laser therapy presented
the same incidence of skin toxicity for both groups. The 3-arm study by Gosselin presented that
none of the products were statistically significant compared to the placebo. The study by Fisher
showed no difference between the non-steroid Biafine cream and the standard of care. The study
by Ho showed that there was very little effectiveness between steroid cream Mometasone furoate
and standard of care, Eucerin cream, but moist desquamation was significantly lower in steroid
cream group. The study by Lam using a film showed no difference between film group and
standard of care group. The study by Nasser using a non-steroid Vitamin D cream was not superior
to Aquacream in preventing radiotherapy-induced skin-toxicity. Finally, the study by Meghrajani
using steroid Hydrocortisone cream showed that CTCAE grade ³ 2 at the end of radiotherapy was
greater in placebo compared to hydrocortisone group , however moist desquamation was
significantly lower in steroid group. The studies with effective results can be seen in Table 5.
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The 34 studies included in the quantitative meta-analysis demonstrated the magnitude of
prevention by intervention type for radiotherapy-induced skin toxicity. The data was depicted
based on how the randomized controlled trials presented their findings. 29 included randomized
controlled trials are presented by risk ratio (RR) and 95% confidence interval (95% CI). 6 included
randomized controlled trials are presented by the standardized mean difference (SMD) and 95%
confidence interval (95% CI) (Figure 2 and Figure 5).
The data was presented primarily by intervention group: non-steroid creams, steroid
creams, laser therapy, oral supplements, and films. The overall RR and 95% CI in the 29 included
studies was 0.82 and (0.74 ,0.90), which represent a 18% protective effect among all of the types
of interventions. By groups, oral supplements presented a 68% protective effect, laser therapy
presented a 48% effect, films presented 46% protective effect, steroid creams presented a 20%
effect, and non-steroid creams presented a 12% protective effect. Overall, oral supplements
presented the largest protective effect in preventing radiotherapy-induced skin toxicity. The overall
SMD and 95% CI for the 6 included studies was -0.64 (-0.85, -0.43), which indicated that
intervention group had a lower mean skin toxicity score than the control group. By groups, oral
supplements presented -0.97 (-1.67, -0.27), and the non-steroid group presented -0.65 (-1.00,
-0.30). Again, the oral supplement group presented a larger protective effect.
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Chapter V. DISCUSSION
This systematic review and meta-analysis aimed to identify and evaluate the effectiveness
of many pharmaceutical and natural intervention agents for the prevention of radiotherapy-induced
skin toxicity. Intervention agents included non-steroid creams, steroid creams, laser therapy, oral
supplements, and films. Of these identified intervention agents, oral supplements proved to
demonstrate the largest protective effect in preventing radiotherapy-induced skin toxicity. Sample
size and number of studies should be taken into consideration as results do not associate statistical
significance with clinical significance.
1. Intervention groups
Three studies that tested oral supplements used glutamine, bran extract, and curcumin. Among
these, the best results were shown by Eda’s glutamine study. Glutamine is known to stimulate
growth hormone and insulin secretion, which is needed to rebuild junctional structures, resulting
in wound healing and tissue repair [28]. The results of Eda’s study showed that 11% of participants
developed grade ³ 2 skin toxicity in intervention group compared to 100% in placebo group.
Huang’s Adlay bran extract also demonstrated promising results. Adlay bran extract is an annual
cereal crop, normally used in Chinese medicine, known to have anti-inflammatory, antioxidant,
and anticancer effects [29]. Huang’s study showed the incidence of grade ³ 2 was significantly
lower in the Adlay bran extract group at 42.2% compared to placebo olive oil group at 75.7%.
Ryan’s curcumin study also proved to show effectiveness within the intervention group. Curcumin
is an active ingredient in the turmeric root that is known to improve skin conditions such as acne,
eczema, and wounds because of its anti-inflammatory and antioxidant properties [30]. Ryan’s
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study presented its results as mean skin toxicity scores and showed a 2.607 ± 0.944 in curcumin
group compared to 3.408 ± 0.554 in the placebo group. In the quantitative meta-analysis, Eda and
Huang’s study were combined to give an overall RR and 95% CI of 0.32 (0.07,1.34), which
indicate a 68% protective effect but with no statistical significance due to uncertainty with a small
sample size of each study and a small number of studies included in the meta-analysis. Ryan’s
study was presented as a SMD value and confidence interval of -0.97 (-1.67, -0.27) which indicates
that oral curcumin had a larger protective effect compared to the placebo group
Laser therapy as an intervention was the second intervention type to present a large
percentage of protective effect for radiotherapy-induced skin toxicity. The 2 studies by Fife and
Robjins tested light emitting diode (LED) photomodulation compared to a placebo. LED
photomodualtion is a process that uses specific indicators of low energy light to regulate or
manipulate cell activity without thermal effect [31]. In addition, other studies have demonstrated
LED photomodulation properties in wound healing and down regulation of inflammatory
mediators [32]. These 2 studies were included in the quantitative analysis and demonstrated an
overall RR and 95% CI of 0.52 (0.12,2.16) indicating a 48% protective effect but with no statistical
significance due to sample size.
Films were the third intervention type with a large percentage of protective effect for
radiotherapy-induced skin toxicity. 4 studies included in the qualitative analysis tested films in
comparison to standard of care or no treatments. Only 2 of those 4 studies were included in the
quantitative analysis due to same reporting outcomes. Films can be made of polyurethane and stick
to the skin surface by a hypoallergenic adhesive. They are semi-permeable, bacteria-proof and can
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remain on the skin for two weeks with no trauma at time of removal [33]. Films act as non-steroid
topical moisturizing agents that prevent moist desquamation. The two included studies in the
quantitative analysis presented an overall RR and 95% CI of 0.54 (0.20, 1.49) indicating 46%
protective effect but with no statistical significance due to sample size.
Both steroid creams and non-steroid creams had the less protective effect for radiotherapyinduced skin toxicity compared to other intervention, but they provided more definitive results due
to the larger number of studies included in the meta-analysis. Steroid creams had an overall RR
and 95% CI of 0.80 (0.66, 0.97) indicating a 20% protective effect and non-steroid creams had an
RR and 95% CI of 0.88 (0.79, 0.99) indicating an 12% protective effect. However, there was a lot
of variation within each group. For example, steroid creams were composed of different active
ingredients, like Hydrocortisone cream 1% or Mometasone Fuorate. Similarly, non-steroid creams
had an abundance of different types of agents. Non-steroid topical products included gels like
Radiacare, Sylimarin 1%, EGF-based cream, honey, and mixture of essential oils. These two
intervention types are distinguished from the other types of intervention groups because of the
number of studies that have tested the nature of steroid creams and non-steroid creams. The amount
of studies raises the sample size which allows for statistical significance of the data.
Overall, all interventions combined gave a significant RR and 95% CI of 0.82 (0.74,0.90),
which indicates a 18% protective effect if any intervention agent is introduced in order to prevent
radiotherapy-induced skin toxicity. This value refutes our hypothesis because the intervention
types, as a whole, indicated a decrease in incidence of grade ³ 2 skin toxicity. However, oral
supplements demonstrated the potential for the largest protective effect, which needs replication
and validation in other studies. With this, statistical significance and clinical significance do not
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correlate, and considerations should be taken with the small number of studies that were
conducted. If more studies tested oral supplements, the statistical power would increase allowing
for stronger evidence to support the effectiveness of oral supplements. For this, further research
should be done in that area.
2. Blinding and Controls
Blinding and controls are two other factors that were considered in this study. Each
randomized controlled trial was unique and conducted in a specific manner. It allowed to evaluate
the data from a different point of view and understand the effect of each intervention critically. As
seen in Figure 3, the data was categorized by blinding method: double, single, no blinding, and
unknown. The double blinding studies presented an RR and 95% CI of 0.79 (0.68,0.92) indicating
an 21% protective effect and statistical significance (Figure 3). Compared to the other studies,
double blinded studies had the greatest protective effect and only one with statistical significance,
which indicated that those studies were able to reduce biases and validate the intervention effects
[34]. Discrepancies within intervention groups were understood as the data was rearranged by
blinding methods. For example, the laser therapy group presented the second largest protective
effect, however individually, the Robjins study showed the statistically significant protective effect
while Fife study showed the null effect. Both studies compared LED photomodulation to a
placebo, but the study by Robjins was double-blinded while the study by Fife was single-blinded,
which may imply the potentially biased results with a single-blinded study. In addition, as the data
was categorized by type of control, the effects of the interventions was understood by the nature
of the comparison groups. The types of controls included: placebos, standard of care, no treatment,
and other treatment. As seen in Figure 4, the studies that used placebos presented the largest
21

protective effect and statistical significance. The interventions compared to placebos presented an
RR and 95% CI of 0.72 (0.55, 0.93), which indicated a 28% protective effect. Compared to the
other studies, placebo-controlled studies identify the full effect of the interventions and typically
represent the intervention treatment as a “new” type of agent. In contrast, studies that compared
interventions to standard of care comparison groups cannot identify the full effect of interventions
because standard of care represents a measure that is currently considered effective for other skin
conditions and researchers try to identify which treatment is better [35]. . The nature of the control
group is an important factor when evaluating the effect of an intervention treatment because it is
critical to identify the full effect of the intervention and know if the effect is superior or not to a
current standard of care.
3. Strengths and Limitations
This systematic review and meta-analysis provided a concrete understanding of the current
research that has been conducted on radiotherapy-induced skin toxicity. The study included 37
studies that had similar participant characteristics and looked for preventive outcomes in the
interventions. The data extraction process was conducted by three reviewers and reviewed twice
in order to minimize errors and resolve discrepancies. All included studies were randomized
controlled trials because it ensured that the data collected was product of experiments that aimed
to reduce selection bias. Also, the grouping of the data ensured a well-rounded understanding of
the nature of the interventions.
Limitations to this study reside with the variations between the way the randomized
controlled trials conducted in 37 studies. Body mass index, pre-chemotherapy, and concurrent
chemotherapy that were identified as possible confounding variables from the literature were
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reported in very few studies and some studies did not take them into consideration at all. However,
these variables between two comparison groups could be comparable with the randomization
process in many of the studies. Also, the majority of studies presented their results from analyzable
data and did not use intention to treat analysis, leading to loss of preservation of randomization
process. Furthermore, the majority of studies had very small sample sizes and hindered the
statistical significance of the results.
This study suggests that further research needs to take place in those intervention groups
that provided the largest protective effect, especially oral supplements. More studies are needed in
those areas in order to generalize findings and opt for more options that can potentially be superior
to standard of care treatments. Also, future studies should report confounding variables like body
mass index, pre-chemotherapy, and concurrent chemotherapy in order to control for them.
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Chapter VI. CONCLUSION
This systematic review and meta-analysis aimed to explore and evaluate available
intervention methods for preventing radiotherapy-induced skin toxicity. Based in the qualitative
and quantitative analysis of the included randomized controlled trials, it can be concluded that the
current available intervention methods reside with non-steroid creams, steroid creams, laser
therapy, oral supplements, and films. Among these, oral supplements proved to have the most
effect in preventing radiotherapy-induced skin toxicity. The results indicate that future research
should aim for double-blinded placebo-controlled studies in order to understand the full effect of
oral supplements. More studies are needed in this area in order to generalize findings and opt for
more options that can potentially be superior to standard of care treatments. This systematic review
and meta-analysis can provide insight to oncologists by providing comprehensive evidence readily
available to offer the best care options for their patients. Finally, this systematic review and metaanalysis can guide a path that leads to a standard treatment for preventing radiotherapy-induced
skin toxicity.
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APPENDIX A: TABLES

Table 1. Radiation Therapy Oncology Group criteria for dermatitis
Grade
Grade 0

Description
No symptoms

Grade 1

Follicular, faint, dull erythema, epilation, dry desquamation, decreased sweating

Grade 2

Tender, bright erythema, patchy moist desquamation, moderate edema

Grade 3

Confluent moist desquamation other than skin folds, pitting edema

Grade 4

Ulceration, hemorrhage necrosis

Grade 5

Death
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Table 2. Common Terminology Criteria for Adverse Events criteria for dermatitis
Grade
Grade 0
Grade 1
Grade 2
Garde 3
Grade 4
Grade 5

Description
No symptoms
Faint erythema or dry desquamation
Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin
folds and creases, moderate edema
Moist desquamation other than skin folds and creases, bleeding induced by minor
trauma or abrasion
Life-threatening consequences, skin necrosis or ulceration of full-thickness dermis,
spontaneous bleeding from involved site, skin graft indicated
Death
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Table 3: PICOS criteria and search terms
Criteria
Participants

Description
Adults women with
breast cancer

Notes
Participants are going to
or plan to go through
radiotherapy

Key Search Term
“breast”
“cancer”

Intervention/E Any interventions used Pharmaceutical or
to prevent radiotherapy- natural agents
xposure
induced skin toxicity

“intervention”

Comparison

Placebo

Comparison groups can
receive placebos or
standard skin care

“control”

Outcome

Skin toxicity grade

Using
RTOG/CTCAE “skin toxicity”
reporting assessment tool
Outcome measures at the
end of radiotherapy

Study design

Randomized controlled Study should use random “randomized
trials
allocation of treatments controlled trial”
and control group(s)
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Synonyms
“mammary”
“neoplasm”
“malignant”
“carcinoma”
“tumor”
“prevent”
“prevention”
“prophylactic”
“therapeutic”
“placebo”
“standard care”
“radiation
dermatitis”
“radiodermatitis”
“skin reaction”
“radiation injury”
“erythema”
“rash”
“RCT”
“randomized
control trial”
“randomized
clinical trial”

Table 4. Characteristics of studies included in review
Patient Characteristics
Author, year

RCT design

Region

#
Participants

Stage of
Cancer

Radiation treatment
External beam radiation is administered to the whole breast for a total dose
of 50Gy in 25 fractions with a 10-16 Gy boost to 85% of the participants

Aysan, 2017

double-blind,
placebocontrolled

Turkey

47

0-III

Ben-David,
2016

phase II,
double-blind

Israel

47

0-II

Germany

70

N/A

Turkey

40

N/A

External beam Radical radiation is administered to the breast and chest for
a total dose of 50 Gy in 25 fractions with a boost of 16 Gy to the chest wall.

USA

33

N/A

Photon beam radiation is administered to the breast and chest for a total of
45- 50.4 Gy in 25 – 28 fractions with a boost of 10-14 Gy

USA

208

0-III

External beam radiation was administered to the breast and supraclavicular
and axillary region for a total dose of 50 Gy in 25 fractions with a boost of
8 Gy.

USA

32

N/A

External beam, tangential radiation was administered to the breast for a
total dose of 50-54 Gy in 25-30 fractions with a boost of 9-10 Gy.

Israel

74

T1T2N0M0

USA

172

N/A

Radiation was administered for a total of 50 Gy.

Iran

40

II-IV

Radiation was administered to the chest for a total of 50 Gy in 25-30
fractions.

0-III

60% of participants received 3D conformal radiation with photons, 18% of
participants received electron and photon radiation, and 23% received
inverse-planned intensity modulated radiation for a total of 50-50.4 Gy in
25-28 fractions

Ghasemi, 2018
Eda, 2015
Fife, 2010
Gosselin, 2010
Enomoto,
2005
Fenig, 2001
Fenig, 2001
Karbasforoosh
an, 2018
Ho, 2018

double-blind,
placebocontrolled
double-blind,
placebocontrolled
Double-blind,
placebocontrolled
double-blinded,
placebocontrolled
double-blinded,
placebocontrolled
3-arm
controlled
Single-blinded,
controlled
double-blinded,
placebocontrolled
Phase III,
double-blinded,
placebocontrolled

USA

124

Photon, Tangential radiation is administered to the whole breast, with the
patients positioned supine, arms above their head for a total dose of 50 Gy
in 25 fractions a boost of 10 and 16 Gy
3D External beam radiation with CT stimulation is administered to the
chest, breast, and nodes for a total dose of 50 Gy in 25 Fractions with a
boost.

External beam radiation was administered to the breast for a total of 50 Gy
in 25 fractions with a boost of 10 Gy.
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Kong, 2016
Huang, 2015

Single-blinded,
controlled
double-blinded,
placebocontrolled

South
Korea

30

I-II

Taiwan

110

0-III

Photon beam radiation was administered to the breast for a total of 50-60
Gy in 25-30 fractions with a boost of 9-10 Gy.
External beam radiation was administered to the breast or chest wall and
nodes for a total of 50.0-50.4 Gy in 25-28 fractions with a boost of 10-14
Gy
Standard radiation was administered to the midline chest, maxilla,
inframammary fold, nipple, outer quadrant, upper inner quadrant, lower
outer quadrant and lower inner quadrant with patients positioned in the
supine position for a total of 54.0± 5.1 Gy in 25 fractions
Photon beam radiation was administered to the whole breast for a total of
46-50 Gy in 25 fractions with an electron boost of 10-16 Gy.

Halm, 2014

unblinded

USA

27

N/A

Kong, 2013

Single-blind,
preliminary

South
Korea

40

N/A

Iran

104

N/A

Standard external beam radiation was administered to the chest wall for a
total of 50 Gy in 25 fractions.

Canada

56

TIS, T1T3

External beam, tangential radiation was administered to the whole breast
for a total of 45.4 Gy for an average of 19.4 fractions with no boost.

Israel

23

Localize
d; DCIS
T12N0M0

Two tangential fields of radiation were administered to the whole breast for
a total of 42.7 Gy or 50 Gy in 16 or 25 fractions with a boost of 10 Gy in 5
fractions.

50

Stage IIII

Standard high-energy photon radiation was administered to the chest wall
for a total of 50 Gy in 25 fractions with a boost of 10 Gy in 5 fractions

Hemati, 2012
Lam, 2019

double-blinded
controlled
Phase III, pair
comparison,
unblinded

Nasser, 2017

Unblinded
(open), selfcontrol

Meghrajani,
2016

double-blinded,
placebocontrolled

Phillipines

Naidoo, 2011

RCT, Phase II,
unblind,
controlled

New
Zealand

81

Miller, 2011

Phase III
double-blind,
placebocontrolled

USA

176

Italy

40

N/A

Belgium

139

Primary
breast
cancer

Leonardi, 2008
Robjins, 2018

double-blind,
vehiclecontrolled
Single-blind,
placebo
controlled

Invasive
breast
cancer or
DCIS
primary
invasive
breast
carcinom
a DCIS

Adjuvant external beam radiation was administered

Continuous or definitive adjuvant external beam radiation was administered
to the breast and chest wall for a total of 50 Gy in 25 fractions.
Standard radiation was administered to the whole breast for a total of 50 Gy
in 25 fractions.
Standard tangential photon beam radiation was administered to the whole
breast, with the participants in supine position, for a total of 50 Gy in 25
fractions with a boost of 16 Gy in 8 fractions.
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Primary
invasive
breast
carcinom
a DCIS
Noninfla
mmatory
or
carcinom
a in situ,
Stage IIV
Tis, T0III, N0II, M0
histologi
cally
confirme
d
carcinom
a

Continuous, definitive, or adjuvant external beam radiation was
administered to the whole breast in 60.7% of participants, chest wall in
39.3% of participants, and regional lymph nodes in 75% of participants for
a total of 45-55 Gy in 36% participants or 55 Gy or more in 64% in 25
fractions.

Rollman, 2015

Double-blind,
placebocontrolled pilot

USA

42

Ryan, 2013

Double-blind,
placebocontrolled

USA

35

Pinnix, 2012

Phase III,
single-blind,
pair comparison

USA

74

Rizza, 2009

3-arm
controlled

Italy

68

N/A

Tangential radiation was administered to the breast, chest wall, and nodes
for a total of 46-52 Gy in 5 fractions a week of 2 Gy, with a boost of 10 Gy.
Tangential photon beams IMRT or VMAT radiation was administered to
the whole breast with the participants in supine position for a total of 50 Gy
in 25 fractions with a boost of 16 Gy.

Pommier,
2003

Phase III,
single-blind,
controlled

France

254

Nonmeta
stic
breast
adenocar
cinoma

Schmeel, 2018

Unblind, pair
comparison

Germany

62

DCIS,
TI-II

Taiwan

39

N/A

Shaw, 2013

Randomized to
receive one of
the three
treatment
combinations,
self-pair
comparison

Standard fractionated radiation was administered for a total of 46.15 ± 4.79
Gy in 29.71 ± 1.61 fractions.

Intensity modulated radiation was administered to the whole breast for a
total of 50 Gy in 25 fractions with a boost of 10-16 Gy

Radiation was administered to the breast, either left or right

Standard radiation therapy with tangential field was administered for the
breast, chest wall, and nodes for a total of 50 Gy in 25 fractions with a
boost of 10 Gy.
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Togoni, 2015

placebocontrolled

Italy

114

N/A

Ulff, 2016

Phase III,
double-blinded

Sweden

202

N/A

Ulff, 2013

Phase III,
double-blinded

Sweden

104

pTNM0IIIC

Graham, 2004

Unblinded paircomparison

Australia

61

Iran

58

II-III

Canada

84

0-III

Sweden

420

N/A

Omidvari,2007
Theberge,
2009
Sharp, 2012

3-arm, doubleblinded
Single-blind,
controlled, noninferiority
Phase III,
double-blinded

External beam radiation with 2 tangential fields and brachytherapy was
administered to the chest wall for a total of 50 Gy in 25 fractions with a
boost.
3D radiation was administered to the breast for a total of 42.56 or 50 Gy in
16 or 25 fractions.
3D radiation was administered to the breast and chest wall for a total of 50
Gy in 25 fractions.
Photon beam radiation applied tangentially was administered to the chest
wall and nodes for a total of 50 Gy in 25 fractions with a boost of 10 Gy to
6 patients.
Superficial X-rays were administed to the chest wall and nodes for a total
of 50 Gy in 25 fractions.
Photon beam radiation with two tangential fields were administered to the
breast or chest wall, with patients in the supine position, for a total of
42.56-50 Gy in 16-25 fractions with a boost of 12 Gy. 12 Gy or 12 fractions
External adjuvant radiation was administered to the fields covering the
breast, chest wall, axillary, and/or supraclavicular lymph nodes for a total
of 42.56 Gy or 50 Gy in 25 fractions with a boost of 16 Gy.
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Table 5. Intervention and Control Indications
Author,
year

Interventio
n/ Control

Sample
size

Mean age
(range)

Type

Aysan,
2017

Intervention

23

55.4 (26-68)

Gel

Control

24

55.4 (26-68)

Intervention

26

Control

BenDavid,
2016
Ghasemi
, 2018

Eda,
2015

Fife,
2010

Gosselin,
2010

Specific Info

Instructions

Boron-based Gel

Apply thin layer over irradiated field 4
times a day starting the first day of RT
until the last day of RT.

Placebo

Hydrogel, composed of 1% w/v
carbopol polymer in distilled water,
buffered with 1M sodium hydroxide

Same as intervention

54

Cream

Melatonin Emulsion Cream

Apply twice a day over treated breast. Do
not apply 2 hours prior to radiation

21

55

Placebo

Emulsion cream without active
ingredient

Same as intervention

Intervention

34

52.9 ± 8.2

Gel

Atrovastatin 1% gel

Apply twice a day from the first RT
session until the last RT session

Control

36

53 ± 12.1

Placebo

Solvent Gel mixture of proylene glycol
(30%), glycerol (30%), water (30%),
and ethanol (10%) with atorvastatin 1%

Same as intervention

Intervention

20

55.3

Oral
Supplement

Oral glutamine

Starting 1 week prior to first RT session
until 1 week after last RT session, 15 gr
per day in 3 divided doses

Control

20

46

Placebo

Capsule consisted of oral glucose
solution

Same as the above

Intervention

18

N/A

Light
therapy

Light emitting diode photomodulation

Control

15

N/A

Placebo

Sham treatment

Intervention

53

56 ±10.8

Cream

Biafine, oil-in-water emulsion with
non-steroidal and anti-inflammatory
properties
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Given before and after each RT session.
administered in gentle waves at 590nm
high energy LED array for 35 seconds, 2
cm away from patients skin in pulses. the
light was on for 250 ms and off for 100 ms
for 100 pulses
No light treatment, but the machine was
placed in the same manner for the same
amount of time as the intervention group
Start the product on the first day of
treatment and apply it twice a day
(morning and night) every day of the week
until treatment was complete

Enomot
o, 2005

Fenig,
2000

Fisher,
2000

Karbasf
oroosha
n, 2018
Ho, 2018

Kong,
2016

Huang,
2015

Intervention

53

55.6 ±8.15

Gel

Intervention
Control

53
49

54.8 ±10.6
55.8 ±11.9

Ointment
Placebo

Intervention

15

62.5 ± 12.2

Gel

Control

15

54.9 ± 8.3

Placebo

Intervention

25

64± 10 (42-82)

Cream

Intervention

24

69 ± 9 (42-80)

Control

25

71± 8 (52-85)

Cream
No
treatment

Radiacare, a gel makes the skin feel
tight once it dries.
Aquaphor, thick ointment
Sterile Water mist

Same as the above
Same as the above
Same as intervention

RayGel, containing glutathione and
anthocyanins

Apply to breast 1-3 hours prior to RT. Use
aloe vera and vitamin E after treatments

Water based gel with beet juice

Same as intervention

Biafine, oil-in-water emulsion with
non-steroidal and anti-inflammatory
properties
Lipiderm, moisturizing cream
No treatment

Instructed to apply twice daily, starting 10
days prior to RT and 10 days post RT.
Same as the above
No instruction

Intervention

83

61.2 (33-84)

Cream

Control

89

61.8 (34-85)

Standard of
Care

Intervention

20

49.5 ± 10.0

Gel

Control

20

47.3 ± 11.46

Placebo

Gel without active ingredient

Begin applying assigned product following
their first radiation treatment and to do this
three times a day until 2 weeks following
completion of their radiation treatments.
A no treatment arm was allowed as an
institutional preference.
Once daily form the 1st day to last day for
5 weeks
Same as intervention

Intervention

70

49 (26-76)

Cream

Mometason Furoate 0.1%

Twice daily from day 1 to 12 days after RT

Control

73

47.5 (30-80)

Placebo

Intervention

15

54.1 (46.474.2)

Ointment

Control

15

50.7 range:
40.1-70.8

Standard of
Care

Eucerin cream
Janugo ointment; consists of
Lithospermi radix, Angelica sinensis,
sesame oil, and beeswax
Skin area clean and washing with
neutral pH soap

Same as intervention
Twice daily, shortly after RT and in the
evening; started at the onset of RT and
continued until 2 weeks after RT
Started at the onset of RT and continued
until 2 weeks after RT

Oral Adlay Bran extract, cereal crop
that has been previously shown to have
anti-inflammatory and antioxidant
properties.

Four capsules a day in two divided doses
(each capsule 500 mg), from the first day
of radiotherapy, and to continue till the last
day of radiotherapy.

Olive Oil, oral capsule

Same as intervention

Intervention

73

51.2 ± 10.5

Oral
Supplement

Control

37

52.1 ± 9.2

Placebo

Biafine, oil-in-water emulsion with
non-steroidal and anti-inflammatory
properties
No treatment
Topical Silymarin 1% gel,

38

Halm,
2014

Kong,
2013

Hemati,
2012

Lam,
2019

Nasser,
2017

Meghraj
ani, 2016

Essential oil mixture essential oils
included Helichrysum (2.5%),
Frankincense (5%) Lavender (5%),
Geranium (5%), Jojoba (32.5%), Aloe
vera (30%), Tamanu (10%); and
evening primrose (10%).
RadiaPlexRX, gel composed of
hyaluronic acid and mannan
polysaccharides.

Three times a day until 1month post
radiation

Intervention

15

55.9±10.8

Oil

Control

12

55.9 ±12.3

Standard of
Care

Intervention

20

57.3

Cream

Control

20

51.8

Standard of
Care

Intervention

51

48.7 ± 10.3

Cream

Control

53

48.1 ± 9.9

Standard of
Care

Gentle washing of the area with baby
soap and not applying a powerful soap
directly to the skin

For 5 weeks during RT and one week
thereafter
BF was applied twice weekly during
treatment. Twice per week from day one of
radiotherapy and continued until treatment
completion.

Human recombinant Epidermal Growth
Factor (EGF cream)
Skin area clean with gentle washing
with or without soap
Topical Silver Sulfadiazine 1%
(antibacterial cream)

Until the 1month follow-up appointment
after the 6-week course of radiation.
Instructed to apply 3 times daily. Start on
onset of RT until 2 weeks after completion
of RT
Start on onset of RT until 2 weeks after
completion of RT.
Applied three times a day, 3 days a week,
for 5 weeks during RT and one week
thereafter

Intervention

56

62.1 (45-86)

Film

3 M Cavilon Barrier film, alcohol-free
film formulated from two polymers.

Other

55

62.1 (45-86)

Standard of
Care

Glaxal Base cream, a non-medicated
cream formulaically similar to aqueous
cream

Started on day one of radiotherapy and
continued until treatment completion.

Intervention

23

63 ±8.0 (3774)

Cream

Vitamin D (Calcipotiol) ointment
cream

Each day, after the delivery of radiation;
randomized to lateral of medial halves

Control

23

63± 8.0 (3774)

Standard of
Care

Intervention

23

50.48

Cream

Hydrocortisone cream 1%,

Control

27

51.78

Placebo

Cream without active ingredient

Aqua cream, moisturizer

39

After 15 min of receiving the daily
radiation dose, Daivonex was applied to
half of the breast and Aqua cream to the
other half.
Apply the cream to the irradiated field
twice a day, starting on the first day of
their radiotherapy until 1 week after the
last radiotherapy session.
Same as intervention

Naidoo,
2011

Miller,
2011

Leonard
i, 2008

Robjins,
2018

Rollman
, 2015

Ryan,
2013

Pinnix,
2012

Intervention

43

N/A

Honey

Manuka honey

Applied twice daily from the 1st day until
10 days post RT

Control

38

N/A

Standard of
Care

Aqueous cream

Same as intervention
Applied 3 mL once daily to the area under
treatment at no less than 4 hours before or
after radiotherapy until completion of the
prescribed course of irradiation.
Same as intervention.

Intervention

90

(Median) 60

Cream

Mometasone Furoate (MMF) cream

Control

86

(Median) 57

Placebo

Cream without active ingredient

Apply the study cream on the irradiated
area three times daily, starting on the first
day of irradiation and continuing until 3
weeks after completion of RT.

Intervention

22

59

Cream

MAS065D, is a water-in-oil cream with
barrier-forming, hydrating and antiinflammatory properties

Control

18

55

Placebo

Cream without active ingredient

Same as intervention.

Intervention

70

56.52±10.54

Laser
Therapy

14 sessions of PBMT (2/week), starting at
the first day of RT.

Control

69

56.92±10.34

Placebo

Intervention

28

N/A

Oil

Control

14

N/A

Placebo

Intervention

17

54.± 63.3

Oral
Supplement

Control

18

61.1± 2.8

Placebo

Laser Therapy (PBMT),
photobiomodulation therapy
Sham treatment, laser device was
switched off, but still made the same
sound as an active laser.
Ultra Emu-Oil, 70% unsaturated fatty
acids, consisting of oleic, linoleic, and
linolenic acid
Cottonseed oil, used in moisturized
cosmetic products and is believed to
have moisturizing qualities
Oral Curcumin, 2.0, contains a
minimum of 95% curcuminoid
Capsule, contains 500 mg of dicalcium
phosphate, excipients and a yellow
food coloring.

Intervention

40

55.4

Cream

Control

25

55.4

Standard of
Care

Same as intervention.
1.5 ml twice daily from 3rd day to 6 weeks
after RT. To start before the 3rd fraction.
Same as intervention.
Four 500mg capsules three times daily
throughout their prescribed course of RT.
Same as intervention.

RadiaPlex

Apply a thin layer 3x a day over the
specified area of the breast (medial or
lateral), beginning one day before the start
of radiotherapy and continuing every day
during the radiotherapy period.

Aquaphor, Petrolatum-based gel

Same as intervention.

40

Rizza,
2009

Pommie
r, 2003

Schmeel,
2018

Shaw,
2013

Togoni,
2015

Ulff,
2016

Ulff,
2013

median 48 (4156)

Cream

a blend of natural extracts containing
Capparis spinosa, Opuntia
coccinellifera and olive leaf extracts

Twice daily to the treatment area from the
first day of radiotherapy

Cream

Biafin, non-steroidal topical product

Same as the above

No
treatment

No treatment

No instruction

Ointment

Calendula

Applied in the onset of RT twice daily or
more until completion of RT

Standard of
Care

Trolamine,

Same as intervention.

Intervention

26

Intervention

24

Control

18

Intervention

126

Control

128

Intervention

62

median 62 (3682)

Film

Control

62

median 62 (3682)

Standard of
Care

median 52 (3865)
median 50 (4558)
56.5 (28.574.5)
55.1 (26.574.3)

Intervention

13

51 (30-76)

Film

Intervention

9

51 (30-76)

Cream

Control

17

51 (30-76)

Other
treatment

Intervention

55

Control

59

Intervention

102

Control

100

Intervention

53

58.2±11.1 (3278)

Hydrofilm polyurethane film dressing

5% Urea lotion
3M Cavilon No Sting Barrier Film, a
non-medicated product that acts as a
physical barrier on the skin against
friction and contamination
Elomet (0.1% topical corticosteroid
cream); Mometasone furoate

Applied before the first RT and replaced
every two weeks
Twice a day to the irradiated control area
adjacent to the Hydrofilm-covered
compartment, starting at the first day of the
radiation treatment.
Every other day, excluding weekends,
during the radiation treatment period,
Same as the above

No treatment

No treatment

Cream

Boswellia cream in Phytosome
(Bosexil ®, anti-inflammatory action)

Twice daily immediately after radiation
therapy and before bed-time in radiation
therapy days, in the morning and at night
in days with no radiotherapy
administration.

Placebo

Placebo-Base Cream

Same as intervention

Cream

Betamethasone-17-valerate cream

Twice a day during the RT and continued
for two weeks after RT

Essex cream moisturizer

Same as intervention

Betamethasone + Essex

Applied over the RT periods and until 2
weeks after RT

58.2±11.1 (3278)
median 64 (2797)
median 62 (2797)

Other
treatment

median 63

Cream

41

Graham,
2004

Omidva
ri, 2007

Theberg
e, 2009

Sharp,
2012

Control

51

median 64

Other
treatment

2 control groups - Essex/Canoderm

Intervention

61

58, range (3088)

Film

3M Cavilon No-string Barrior Film

Control

61

58, range (3088)

Other
treatment

sorbolene cream (10% glycerin)

Intervention

19

47.6 (35-66)

Cream

Betamethasome, steroid cream

Intervention

17

52.5 (39-65)

Petrolatum

Control

15

48 (34-60)

Cream
Other
treatment

Twice weekly to the medial and three
times weekly to the lateral compartment.
Twice daily to either lateral or medial as
assigned from the start of RT until 2 weeks
after completion
Twice daily from the first day of RT to two
weeks after RT
Same as the above

No treatment

No treatment

Intervention

40

59.5 ± 10.6

Deoderant

Deodorant without aluminum

A daily basis during RT

Control

44

58.8 ± 10.6

Standard of
Care

No-deodorant

No treatment

Calandula Weleda, contains extracts of
marigold plant (Calendula officinalis
10%), wool fat and sesame oil.

Apply a thin layer of the assigned cream
twice a day, starting at the onset of RT and
continuing until two weeks after final RT
session, or until the ARSR was healed.

Standard of Care, aqueous cream
without parabenes

Same as intervention

Intervention

203

58

Cream

Control

208

58

Standard of
Care

42

Same as intervention

Table 6. Outcome measurements and results by intervention type
Study

Interventiondetail

Control-detail

Assessment
tool

Assessm
ent timepoint

Outcome
variable

Result in
Interventi
on

Results in
control

Time to
grade 2
Grade 2+

44.2 days

46.6 days

39/110
(35.5%)
7/56
(12.5%)

45/110
(40.9%)
23/56
(41.1%)

MD

20/61
(33%)

28/61
(46%)

A. Film
Shaw,
2013
Lam,
2019
Schmeel,
2018

3M Cavilon
Barrier Film
3M Cavilon
Barrier film
Hydro-film

Graham,
2004

3M Cavilon
Barrier Film

No treatment

CTCAE

LDRT

Supportive
skin care
Aqueous
cream (5%
urea +
Eucerin)
Sorbolene
(with 10%
glycerin &
sorbitol)

modified
RTOG
RTOG

1W-post
RT
LDRT

RTOG

Max.
over 12
wks RT

Grade 2+,
MD

B. Laser Therapy
Fife,
2010
Robjins,
2018

Light emitting
diode photomodulation
Photobiomodulation

Placebo

CTCAE

LDRT

Grade 2+

12/18
(66.7%)

10/15
(66.7%)

Placebo

RTOG

LDRT

Grade 2+

4/60
(6.7%)

18/60
(30%)

0/20 (0%)

9/20
(45%)

30/55
(54.6%)
19/26
(73.1%);
2.02± 0.56
52/126
(41%)
45/203
(2342%)

42/59
(71.2%)
17/18
(94.4%);
3.19± 0.77
81/128
(63%)
38/208
(19%)

2/21
(10%)
40/65
(61.5%)
19/53
(36%)

16/18
(88%)
31/65
(47.7%)
19/45
(40%)

17/17
(100%)
21/53
(40%)

14/15
(93.3%)
19/45
(40%)

C. Non-steroid topical products
C.1. Herbal extracts
RTOG/
LDRT
Grade 2+
CTCAE

Karbasfo
rooshan,
2018
Togoni,
2015
Rizza,
2009

Silymarin 1%
gel

Placebo

Boswellia
cream
Herbal extracts

Placebo

RTOG

LDRT

Grade 2+

No treatment

Modified
RTOG

Pommier
, 2003
Sharp,
2012

Calendula

Over 8
wks of
RT
LDRT

Leonardi,
2008
Pinnix,
2012
Gosselin,
2010

MAS065D
cream
RadiaPlex
cream
RadiaCare gel

TrolamineRTOG
based
Aqueous
RTOG
2Wcream (Essex)
postRT
C.2 Hyaluronic acid-based products
Placebo
CTCAE
3WpostRT
PetrolatumCTCAE
1Wbased
postRT
Placebo
RTOG
LDRT

Grade 2+,
Average
score
Grade 2+

Omidvari
, 2007
Gosselin
2010

Petrolatum

Calendula

Aquaphor
ointment

C.3 Petroleum-based products
No treatment
RTOG
2WpostRT
Placebo
RTOG
LDRT

43

Grade 2+

Grade 2+,
MD
Grade 2+
Grade 2+
Grade 2+
Grade 2+

Fenig,
2001

Biafine cream

Fenig,
2001

Biafine cream

C.4 Trolamine-based products
Aqueous
RTOG
LDRT
(Lipiderm)
cream
No treatment
RTOG
LDRT

Rizza,
2009

Biafine cream

No treatment

modified
RTOG

Over 8
wks RT

Gosselin,
2010
Fisher
2000

Biafine cream

Placebo

RTOG

LDRT

Biafine cream

Kong,
2016

Juango
OintmentPlant
metabolites
Raygel Reduced
glutathione

Supportive
RTOG
6wGrade 2+
skin care
postRT
C.5 Other non-steroidal topical products
Supportive
RTOG
Over
Grade 2+
skin care
4WpostRT

Enomoto
, 2005

Placebo

RTOG

LDRT

Silver
sulfadiazine
1% cream
Aqueous
(Lipiderm
cream)
Atorvastatin
1% gel
Calcipotriol
(Vitamin D)
ointment
Deodorant

Supportive
skin care

RTOG

1WpostRT

No treatment

RTOG

LDRT

Placebo

RTOG

LDRT

Aqueous
cream

RTOG

No treatment

RTOG

Over
2WpostRT
LDRT

Emu oil

Placebo

CTCAE

Epidermal
growth factorbased cream

Supportive
skin care

RTOG

Halm,
2014

Essential oil
mixture

RTOG

Naidoo,
2011
BenDavid,
2016
Aysan,
2017

Manuka
Honey
Melatonincontaining
emulsion
Boron-based
gel- Mineral

Hyaluronic
acid-based
RadiaPlex
Aqueous
cream
Placebo
Placebo

RTOG

Hemati,
2012
Fenig,
2001
Ghasemi,
2018
Nasser,
2017
Theberge
, 2009
Rollman,
2015
Kong,
2013

RTOG
CTCAE

44

Grade 3+,
average
score
Grade 3+,
average
score
Grade 2+,
average
score
Grade 2+

10 (59%);
1.6±0.9

6 (30%);
1.7±1.1

6 (30%);
1.7±1.1

5(31%);
2.2 1.2

22/24
(91.7%);
2.40± 0.57
24/53
(46%)
27/66
(41%)

17/18
(94.4%);
3.19± 0.77
19/45
(40%)
26/74
(35%)

7/15
(46.7%)

11/14
(78.6%)

Total
score for
whole
breast
Grade1/2/
3, total
score
Grade 3+,
average
score
Average
score
Grade 2+

93.7±60.5

123 ±58.4

43/51
(84%)

50/51
(98%)

10(59%);
1.6±0.9

5(31%);
2.2±1.2

0.72±0.7

1.00±0.6

17/23,
(73%)

18/23,
(78%)

Grade 2+

12/40
(30%)
25/28,
(90%)
14/20
(70%)

15/44
(34%)
11/14,
(80%)
18/20
(90%)

6W-post
RT
Over 5
wks RT
& 6 wks
f/u
LDRT

Grade 2+

Average
score

1.38 ±0.65

1.65±0.60

10 days
postRT
2WpostRT

Grade 2+

16/43
(37.2%)
41%

22/38
(57.8%)
90%

LDRT

Grade 2+

8/23
(34%)

16/24
(67%)

Grade
1/2/3

Grade 1+

D. Steroid topical products
Omidvari
,2007
Omidvari
,2007
Ulff,
2016
Ulff,
2013
Shaw,
2013
Miller,
2011

Betamethasone

No treatment

RTOG

Betamethasone

Petroleumbased
Aqueous
cream (Essex)
Aqueous
cream (Essex)
No treatment

RTOG

Placebo

CTCAE

Ho, 2018

Mometasone
furoate

CTCAE

Shaw,
2013
Meghraja
ni, 2016

Mometasone
furoate
Hydrocortison
e 1% cream

Aqueous
cream
(Eucerin)
3M Cavilon
Barrier Film
Placebo

Betamethasone
Betamethasone
Mometasone
furoate
Mometasone
furoate

2WpostRT
2WpostRT
LDRT

RTOG
RTOG
CTCAE

Over 5
weeks
LDRT
Over
2WpostRT
2WpostRT

CTCAE

LDRT

CTCAE

LDRT

Grade 2+

16/19
(84.2%)
16/19
(84.2%)
32/102
(31%)
31/53
(58%)
52 days

14/15
(93.3%)
17/17
(100%)
71/100
(71%)
42/49
(86%)
43 days

30/84
(35%)

37/82
(45%)

Grade 2+,
MD

55/64
(86%)

58/60
(97%)

Time to
grade 2
Grade 2+,
MD

53.4 days

44.5 days

17/23
(74%)

14/27
(52%)

33/73
(45.2%)
2/18
(11%)
2.607±
0.944

28/37
(75.7%)
20/20
(100%)
3.408±
0.554

Grade 2+
Grade 2+,
MD
Grade 2+,
Grade 3+
Time to
grade 2
Grade 2+

E. Oral Supplement
Huang,
2015
Eda,
2015
Ryan,
2013

Adlay Bran
extract
Glutamine Amino acid
Curcumin Herbal

Placebo

RTOG

LDRT

Grade 2+

Placebo

RTOG

Grade 2+

Placebo

Adapted
RTOG/CTC
AE

1WpostRT
LDRT

LDRT: Last day of radiotherapy
MD: Moist desquamation
RTOG: Radiation Therapy Oncology Group
CTCAE: Common Terminology Criteria for Adverse Events
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Average
score, MD

APPENDIX B: FIGURES

Figure 1. PRISMA Flow Diagram: Process of study selection for intervention for acute radiationinduced skin toxicity
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Figure 2. Meta-analysis of effects of interventions on prevention of grade 2+ skin toxicity:
subgroup analysis by intervention type (30 studies and 34 comparisons)
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Figure 3. Meta-analysis of effects of interventions on prevention of grade 2+ skin toxicity:
subgroup analysis by blinding (30 studies and 34 comparisons)
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Figure 4. Meta-analysis of effects of interventions on prevention of grade 2+ skin toxicity:
subgroup analysis by control type (30 studies and 34 comparisons)
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Figure 5. Meta-analysis of effects of interventions on reduction of radiodermatitis score by
intervention type (6 studies, 9 comparisons)
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